araag2/HINT huggingface dataset:
Clinical trial NCT00660374 (phase 2, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin nph, ex1000
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes for at least 12 months

          -  Current NPH treatment for at least 3 months - alone or as the only insulin in
             combination with OADs

          -  Body Mass Index (BMI) less than or equal to 40 kg/m2

          -  HbA1c less than or equal to 9.5%

          -  FPG less than or equal to 12 mmol/L

        Exclusion Criteria:

          -  Treatment with Glucagon-like peptide 1 mimetics or dipeptityl peptidase IV inhibitors

          -  Treatment with more than 1 IU/kg NPH insulin daily

          -  Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the
             Investigator

          -  Known or suspected allergy to trial products or related products

          -  Receipt of any investigational drug within one month prior to this trial

          -  Any other condition that the Investigator feels would interfere with trial
             participation or evaluation of results, e.g. shiftworkers
Clinical trial NCT01487200 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: fx006 10 mg, fx006 40 mg, fx006 60 mg, tca ir 40
SMILES: OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1, OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1, [H][C@@]12C[C@@H](O)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Main Inclusion Criteria:

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Male or female >=35 years of age

          -  Diagnosis of unilateral or bilateral OA of the knee for at least 6 months prior to
             Screening with confirmation of OA according to American College of Rheumatology
             Criteria for Classification of Idiopathic OA of the Knee (clinical and radiological)
             based on an X-ray performed within 6 months prior to Screening or during the Screening
             period

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Willingness to abstain from use of the protocol-specified restricted medications

        Main Exclusion Criteria:

          -  History of Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing
             spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis or
             amyloidosis

          -  History of arthritides due to crystals (e.g., gout, pseudogout)

          -  History of infection in the index joint

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Unstable joint (such as a torn anterior cruciate ligament)

          -  IA corticosteroid (investigational or marketed) in any joint within 3 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  Oral, inhaled or intranasal corticosteroids (investigational or marketed) within 1
             month of Screening

          -  Prior arthroscopic or open surgery of the index knee within 12 months of Screening

          -  Planned/anticipated surgery of the index knee during the study period

          -  History of or active malignancy, with the exception of resected basal cell carcinoma,
             squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ
             within 5 years

          -  Insulin-dependent diabetes

          -  History of or active Cushing's syndrome

          -  Any other clinically significant acute or chronic medical conditions (e.g.,
             uncontrolled diabetes)

          -  Skin breakdown at the knee where the injection would take place

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing
Clinical trial NCT00517699 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab [mabthera/rituxan], methotrexate, cytarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    study was terminated early due to lack of enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-80 years of age;

          -  histological diagnosis of primary central nervous system lymphoma;

          -  B-cell proliferation verified by positive staining for CD20;

          -  >=1 measurable lesion.

        Exclusion Criteria:

          -  prior chemotherapy, other than corticosteroids, >=6 weeks before and after diagnosis
             or surgery;

          -  history of prior cranial irradiation;

          -  evidence of plurisystemic non-Hodgkin's lymphoma;

          -  other active malignant disease (other than basal cell or squamous cell cancer of
             skin,or cancer in situ of cervix;

          -  uncontrolled active infection.
Clinical trial NCT00478322 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2, obesity
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: placebo, incb013739
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Have an established diagnosis of Type 2 Diabetes as determined by the investigator.

          2. Females will be postmenopausal for at least 1 year with documented FSH > 30 IU/L.

        Exclusion Criteria:

          1. Hypertriglyceridemia > 500 mg/dL at screening.

          2. BMI > 40 kg/m2.

          3. Receiving thiazolidinediones, insulin, or exenatide within the 3 months prior to
             screening.

          4. History or clinical manifestations of Addison's disease, Cushing's Syndrome, or other
             disorders involving glucocorticoids or mineralocorticoids.

          5. Current treatment or treatment within 30 days or five half-lives (whichever is longer)
             prior to the first dose of study medication with another investigational medication or
             current enrollment in another investigational protocol.
Clinical trial NCT00709826 (phase 2, status: completed)
Conditions: pancreatic cancer, metastatic pancreatic cancer
ICD codes: C25.3, C25.3
Drugs: gemcitabine, placebo, erlotinib, apricoxib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CCOC1=CC=C(C=C1)C1=CC(C)=CN1C1=CC=C(C=C1)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the pancreas that is
             locally advanced or metastatic.

          2. Life expectancy greater than or equal to 3 months.

          3. Patients must have measurable disease by RECIST.

          4. ECOG PS of 0, 1, or 2.

          5. Negative serum pregnancy test at the time of first dose for women of childbearing
             potential.

        Exclusion Criteria:

          1. Previous chemotherapy as primary treatment for locally advanced or metastatic
             pancreatic cancer(stage 3 T3 and T4, and all stage 4).

          2. RT within 2 weeks or chemotherapy within 3 weeks or noncytotoxic investigational
             agents within 4 weeks of initiating study treatment.

          3. Evidence of New York Heart Association class III or greater cardiac disease.

          4. History of myocardial infarction, stroke, ventricular arrhythmia.

          5. Symptomatic central nervous system metastases.

          6. Pregnant or nursing women.

          7. Hypersensitivity or intolerance to apricoxib, erlotinib, gemcitabine, sulfonamides,
             aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs).

          8. History of upper gastrointestinal bleeding, ulceration or perforation. History of
             lower GI bleeding, ulceration, or perforation within 12 months.

          9. Previous anti-EGFR kinase therapy.
Clinical trial NCT00451932 (phase 2, status: completed)
Conditions: liver transplantation
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: fk778
SMILES: O\C(CCC#C)=C(\C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients at least 18 years of age and not older than 65 years.

          -  Female patients of child bearing potential must have a negative serum pregnancy test
             prior to enrollment and must agree to practice effective birth control during the
             study.

          -  Male patients must agree to practice effective birth control methods during the study.

          -  Patient is a recipient of a primary whole cadaveric liver transplant

        Exclusion Criteria:

          -  Patient has previously received or is receiving an organ transplant other than a
             liver.

          -  Patient has received an ABO incompatible donor liver.

          -  Patient or donor is known to be HIV positive.

          -  Patient has a current malignancy or a history of malignancy (within the past 5 years),
             except non-metastatic basal or squamous cell carcinoma of the skin that has been
             treated successfully.

          -  Patient is being transplanted for hepatic malignancy with a single nodule greater than
             5.0 cm in diameter or 2 or more nodules with at least one > 3.0 cm.

          -  Patient has a serum creatinine >175 µmol/L at baseline. Patient has uncontrolled
             concomitant infections and/or severe diarrhoea, vomiting, active upper
             gastro-intestinal tract malabsorption or an active peptic ulcer or any other unstable
             medical condition that could interfere with the study objectives.

          -  Patient who is receiving or may require warfarin or fluvastatin during the study.

          -  Patient is participating in another clinical trial and/or is taking or has been taking
             an investigational drug in the 28 days prior to transplant
Clinical trial NCT00113256 (phase 2/phase 3, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: rubitecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=C(C1=C3)[N+]([O-])=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  The patient is at least 18 years of age.

          -  The patient has histologically or cytologically confirmed, non-resectable, Stage II-IV
             primary adenocarcinoma of the pancreas.

          -  The patient has had a baseline computed tomography (CT) scan, or magnetic resonance
             imaging (MRI), to evaluate tumor(s) within 28 days prior to randomization.

          -  The patient has never been treated with prior chemotherapy, with the exception of
             low-dose 5-fluorouracil (5-FU) as a radiation sensitizer.

          -  The patient has sufficiently recovered from the effects of previous surgery (no less
             than 3 weeks prior to randomization), radiotherapy, and/or immunotherapy (no less than
             4 weeks prior to randomization).

          -  The patient's estimated life expectancy is at least 12 weeks.

          -  The patient has a Karnofsky Performance Status between 50 and 100.

          -  The patient has adequate bone marrow function.

          -  The patient has adequate hepatic and renal function.

        Exclusion Criteria:

          -  The patient has any active, uncontrolled infection requiring antibiotics.

          -  The patient has any serious, uncontrolled concomitant systemic disorder.

          -  The patient has surgery scheduled within 8 weeks following initiation of treatment.

          -  The patient is pregnant or nursing.

          -  The patient is not capable of consistent oral intake of at least 3 L/day of fluid
             and/or requires constant intravenous (IV) hydration or frequent tube feeding.

          -  The patient is receiving any investigational agent(s) or has been a participant in a
             clinical trial within the last 30 days.
Clinical trial NCT00080782 (phase 2, status: terminated)
Conditions: metastatic cancer, prostate cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: celecoxib, doxorubicin hydrochloride
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    low accrual due to competing trial.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of androgen-independent prostate cancer

               -  Osteoblastic metastases

               -  No predominant visceral metastases

          -  Progressive disease after response to prior induction chemotherapy (prostate-specific
             antigen decline of at least 50% from baseline after 16 weeks of treatment)

          -  No symptomatic lymphadenopathy (i.e., scrotal or pedal edema)

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Adequate physiologic reserves

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radionuclide therapy

        Surgery

          -  Not specified

        Other

          -  No more than 3 prior cytotoxic treatments

          -  More than 6 months since prior celecoxib or rofecoxib
Clinical trial NCT00293813 (phase 2, status: completed)
Conditions: postmenopausal osteoporosis
ICD codes: N95.0, N95.2
Drugs: alendronate, denosumab, placebo
SMILES: COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Postmenopausal, ambulatory women between 50 and 70 years old who are generally in good
             health.

          -  Must have low bone mineral density and meet specific eligibility criteria.

        Key Exclusion Criteria:

        -Subjects must not currently be receiving any medication that affects bone metabolism or
        have an underlying condition that affects their ability to take alendronate or receive
        denosumab.
Clinical trial NCT00514371 (phase 2/phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: tanespimycin, bortezomib
SMILES: [H]/C1=C([H])/[C@]([H])(OC)[C@@]([H])(OC(O)=N)C(C)=C([H])[C@]([H])(C)[C@@]([H])(O)[C@]([H])(C[C@]([H])(C)CC2=C(NCC=C)C(=O)C=C(N=C(O)\C(C)=C\1/[H])C2=O)OC, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Good performance status

          -  Histologic evidence of multiple myeloma

          -  Have had at least three prior treatment regimens for multiple myeloma that included
             both bortezomib and lenalidomide

          -  No prior treatment with a heat shock 90 inhibitor or an investigational proteasome
             inhibitor

          -  No known infections of HAV, HBV, HCV, or HIV

          -  No chemotherapy, radiation therapy, or immune therapy for three weeks prior to
             enrollment.
Clinical trial NCT02212119 (phase 2, status: completed)
Conditions: dementia, paratonia
ICD codes: G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17
Drugs: botulinum toxin, saline
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Severe cognitive impairment (complete dependency in all activities of daily living
             (ADLs)

          -  Diagnosis of Alzheimer's disease, vascular dementia,or frontotemporal dementia

          -  Score> 3 on the paratonic assessment instrument, with paratonic rigidity in an arm(s)
             interfering in the provision of care

        Exclusion Criteria:

          -  Alternate etiologies for increased tone

          -  Botulinum toxin 6 months preceding the study
Clinical trial NCT01128335 (phase 2, status: completed)
Conditions: liver transplantation
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: mmf(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12
Eligibility criteria:

        Inclusion criteria:

          -  Recipients of any race, 18 years or older

          -  Recipients of primary de novo orthotopic liver transplant from a deceased donor

          -  Recipients of a kidney with a cold ischemia time < 30 hours

          -  HCV-negative recipients

        Exclusion criteria:

          -  Prior organ/cellular transplant or multiple organ transplant

          -  MELD-score > 35

          -  HCC > Milan criteria

          -  Donor age < 12 years

          -  Cold ischemia > 15 hours

          -  Patients who are treated with drugs that are strong inducers or inhibitors of
             cytochrome P450 3A4 (CYP3A4) or drugs with QT-prolonging properties

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00422461 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: pf-00489791, pf-00489791, pf-00489791, placebo
SMILES: CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males and/or Females of non-childbearing potential between 18 and 70 years of age

          2. History of mild to moderate hypertension

        Exclusion Criteria:

          1. Type 1 or 2 diabetes on prescribed medications

          2. Secondary, severe, or malignant hypertension

          3. History of a significant cardiovascular event within the last 12 months of enrollment
Clinical trial NCT00353665 (phase 2/phase 3, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: memantine (ebixa), riluzole, placebo
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2, NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Definite or probable disease - revise El Escorial criteria

          -  Normal blood tests

          -  Riluzole treatment during 1 month or more

          -  EMG in accordance with El Escorial criteria

        Exclusion Criteria:

          -  Other diseases (such as PNP)

          -  Both ADM muscles < 3 on MRC scale

          -  Conduction block on nerve conduction tests

          -  Disease duration > 3 years

          -  ALS-FRS < 25

          -  Forced vital capacity - <60%
Clinical trial NCT01227707 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab [avastin], capecitabine [xeloda], bevacizumab [avastin], 5-fluorouracil, leucovorin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, >=18 years of age

          -  Patients with confirmed rectal cancer who are subject to surgery and would benefit
             from pre-operative combined chemo-radiotherapy

          -  Measurable and/or evaluable lesions according to RECIST criteria

          -  EOCG performance status 0-1

        Exclusion Criteria:

          -  Prior radiotherapy or chemotherapy for rectal cancer

          -  Untreated brain metastases or spinal cord compression or primary brain tumors

          -  Chronic daily treatment with high-dose aspirin (>325 mg/day) or other medications
             known to predispose to gastrointestinal ulceration

          -  Co-existing malignancies, or malignancies diagnosed within the last 5 years, with the
             exception of basal and squamous cell cancer, or cervical cancer in situ.
Clinical trial NCT00191139 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gemcitabine, docetaxel, cisplatin, etoposide
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  histologic or cytologic proof of single primary non-small cell lung cancer

          -  No prior chemotherapy or radiation therapy

          -  no prior malignancy

        Exclusion Criteria:

          -  pregnancy or breastfeeding

          -  serious concomitant systemic disorder

          -  unintentional weight loss greater than 10%
Clinical trial NCT00710970 (phase 2, status: completed)
Conditions: urinary bladder neoplasms
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: tamoxifen
SMILES: OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Patients previously diagnosed with bladder cancer who have already received 1-2
             systemic therapy regimens (chemotherapy or biological therapy or both) but including
             at least one chemotherapy regimen.

          -  Patients who have had the cancer spread to other parts of the body.

          -  Patients must have adequate liver function.

        Exclusion Criteria:

          -  Patients who have uncontrolled nervous system metastasis

          -  Patients who are pregnant

          -  Patients who have had systemic therapies within the past 4 weeks

          -  Patients who plan to have major surgery within 2 weeks

          -  Patients who have Grade III/IV heart problems

          -  Patients who have severe and/or uncontrolled medical disease.

          -  Patients who might be at high risk for deep vein thrombosis